About Sensei Biotherapeutics
Sensei Biotherapeutics is a publicly listed company based in Gaithersburg (United States) founded in 1999. Immunotherapies for cancer treatment are developed using proprietary platforms. It operates on a HealthTech model. Sensei Biotherapeutics has raised $114.4 million across 7 funding rounds from investors including Olympus, Dai Nippon Printing and Mitsubishi Corporation. The company has 15 employees. Sensei Biotherapeutics has completed 1 acquisition, including Faeth Therapeutics. Its chief executive, as recorded, is John Celebi. Sensei Biotherapeutics offers products and services including Conditionally Active Antibodies and Solnerstotug. Its focus areas include Biotechnology and Immuno-Oncology. Its legal entity is Sensei Biotherapeutics, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Sensei Biotherapeutics is engaged in discovering innovative cancer treatments by leveraging the immune systems mechanisms. The company is dedicated to creating conditionally active antibodies that operate selectively within the tumor microenvironment. These therapies are designed to address challenging immuno-oncology targets, potentially offering new options for patients with cancer. Research and development efforts are centered on unlocking previously undruggable targets to advance treatment possibilities in the healthcare sector.
- Headquarters Gaithersburg, United States
- Employees 15
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website senseibio.com
- Social LinkedIn X
- Legal Name Sensei Biotherapeutics, Inc.
- Net Profit-$21.09 M (USD)30.08as on Dec 31, 2025
- EBITDA-$22.15 M (USD)28.81as on Dec 31, 2025
- Total Equity Funding$114.4M (USD)
in 7 rounds
- Latest Funding Round$30M (USD), Series B
Jan 2021
- InvestorsOlympus
& 11 more
- Employee Count15
- Investments & Acquisitions
Products & Services of Sensei Biotherapeutics
Sensei Biotherapeutics offers a comprehensive portfolio of products and services, including Conditionally Active Antibodies and Solnerstotug.
Therapies are developed to target tumor microenvironment selectively.
Drug is designed for PD-(L)1 resistant tumor treatment.
Funding Insights of Sensei Biotherapeutics
Sensei Biotherapeutics has successfully raised a total of $114.4M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $30 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $114.4M
- Total Rounds 7
- Last Round Series B β $30M
- First Round $3M
(May 2002)
- Investors Count 12
All 7 funding rounds of Sensei Biotherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $30M | Series B | β | Apeiron Investment Group, Catalio Capital Management | |
| Oct 2020 | $28.5M | Series A | β | Cambrian BioPharma | |
| Jan 2020 | $25M | Series A | β | β | β |
| Dec 2015 | $15M | Series E | β | β | β |
| Jun 2006 | $8.9M | Series D | β | β | β |
| Jul 2005 | $7M | Series A | β | β | |
| May 2002 | $3M | Unspecified | β | MedImmune | β |
12 investors in total: 12 institutional.
Investors in Sensei Biotherapeutics
Sensei Biotherapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Olympus, Dai Nippon Printing and Mitsubishi Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm backed by Christian Angermayer | apeiron-investments.com | Sliema, Malta | ||
Venture capital is provided to biomedical technology startups. | cataliocapital.com | New York, United States | ||
Investment management services are provided focusing on healthcare innovation. | puravidainvestments.com | New York, United States | ||
Future Ventures is focused on early-stage venture capital investments. | future.ventures | Los Altos, United States | ||
Venture capital fund backed by the Christian family office | presight.vc | West Hollywood, United States | ||
Medicines and therapies are developed for healthcare applications. | 2019 | cambrianbio.com | Brooklyn, United States | |
Natural gas and petroleum are distributed and traded globally. | 1954 | mitsubishicorp.com | New York, United States | |
Manufacturer of imaging and surgical products | 1919 | olympus-global.com | Tokyo, Japan | |
Chemical products and semiconductor materials are manufactured and supplied internationally. | 1926 | shinetsu.co.jp | Tokyo, Japan | |
Property and casualty insurance services are provided in Japan. | tokiomarine-nichido.co.jp | Chiyoda City, Japan |
Investor details for Sensei Biotherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sensei Biotherapeutics
22 people are tracked at Sensei Biotherapeutics (8 in leadership, 13 in board & advisors, 1 in team); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
John Celebi | CEO & President | Leadership |
Christopher Gerry | VP, General Counsel | Leadership |
John K. Celebi | President and CEO | Leadership |
Juan Parra | Sr. Director, Fp&a And Business Operations | Leadership |
Erin Colgan | CFO | Leadership |
Ciaran Flood | Senior Director Of Finance And Controller | Leadership |
Humberto Moran | Vice President of Technical Operations and Maryland Site Lead | Leadership |
Stephanie Krebs | Chief Business Officer | Leadership |
Sara Pai | Advisor | Board & advisors |
Robert Schreiber | Advisor | Board & advisors |
Alain Algazi | Advisor | Board & advisors |
Daniel H. Sterman | Advisor | Board & advisors |
Samuel Broder | Director | Board & advisors |
Bob Holmen | Director | Board & advisors |
James Peyer | Director | Board & advisors |
Tom Ricks | Director | Board & advisors |
Maura Gillison | Advisor | Board & advisors |
William Ringo | Chair | Board & advisors |
Dan Sterman | Advisor | Board & advisors |
Kristian Humer | Director | Board & advisors |
2 more people are available in the full profile.
Complete people profiles for Sensei Biotherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sensei Biotherapeutics
Sensei Biotherapeutics is a publicly listed company on the NASDAQ with ticker symbol SNSE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Feb 2021
- Listed onNASDAQ: SNSE
- Listed entitySensei Biotherapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS81728A2078
- Share price$23.40 (-1.52% on the day) · 2026-05-11
- Market capitalisation$31.4M
- EPS (diluted, trailing year)$-19.16
- Volume (last session)16,234
- Analyst consensusStrong buy
Financials of Sensei Biotherapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$21.1M | -$22.1M | |
| 2024 | -$30.2M | -$31.1M | |
| 2023 | -$34.1M | -$36.5M | |
| 2022 | -$48.6M | -$47.3M | |
| 2021 | -$36.8M | -$36.8M |
Detailed financial statements for Sensei Biotherapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sensei Biotherapeutics
Sensei Biotherapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Faeth Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Personalized nutritional programs against cancer are provided. | faeththerapeutics.com | San Francisco, United States | 2019 | Feb 2026 | β’β’β’β’ |
Complete acquisition details for Sensei Biotherapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Sensei Biotherapeutics
5 dated milestones of Sensei Biotherapeutics across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Sensei Biotherapeutics is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Series B, of $30.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Faeth Therapeutics.
Competitors of Sensei Biotherapeutics
Sensei Biotherapeutics has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Sensei Biotherapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sensei Biotherapeutics
The website of Sensei Biotherapeutics (senseibio.com) receives about 4.5K visits a month and ranks #4,696,262 among all websites worldwide, #5,576 in Biotechnology and Pharmaceuticals.
- Monthly visits4.5K
▲ 14.5% vs previous month
- Unique visitors1.7K
per month
- Global rank#4,696,262
among all websites
- Category rank#5,576
Health · Biotechnology and Pharmaceuticals
- Bounce rate48%
- Pages per visit1.5
- Average visit7 sec
- DevicesDesktop 23% Β· Mobile 78%
Websites whose visitors overlap most with Sensei Biotherapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| immunomix.com | 100% | 2.7K | #5,105,289 | View details | |
| americangene.com | 99% | 16.6K | #1,411,276 | View details | |
| maxcyte.com | 97% | 11.2K | #1,958,980 | View details | |
| hummingbirdbioscience.com | 97% | 5K | #1,579,101 | View details | |
| macrogenics.com | 67% | 10.4K | #2,000,657 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 11 similar websites and full traffic analytics for Sensei Biotherapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as Sensei Biotherapeutics (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sensei Biotherapeutics
Complete news archive for Sensei Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sensei Biotherapeutics
Sensei Biotherapeutics was founded in 1999 and raised its 1st funding round 3 years after it was founded.
Sensei Biotherapeutics is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
John Celebi is the CEO of Sensei Biotherapeutics, as recorded in our data.
Sensei Biotherapeutics is a funded company, having raised a total of $114.4M across 7 funding rounds to date. The company's 1st funding round was a Unspecified of $3M, raised on May 2002.
Sensei Biotherapeutics has 15 employees.
Sensei Biotherapeutics is engaged in discovering innovative cancer treatments by leveraging the immune systems mechanisms. The company is dedicated to creating conditionally active antibodies that operate selectively within the tumor microenvironment. These therapies are designed to address challenging immuno-oncology targets, potentially offering new options for patients with cancer. Research and development efforts are centered on unlocking previously undruggable targets to advance treatment possibilities in the healthcare sector.
Sensei Biotherapeutics offers Conditionally Active Antibodies and Solnerstotug.
Yes, Sensei Biotherapeutics is publicly traded on NASDAQ under the ticker symbol SNSE.
Sensei Biotherapeutics has made 1 acquisition, including Faeth Therapeutics.
Sensei Biotherapeutics has 12 investors. Key investors include Olympus, Dai Nippon Printing, Mitsubishi Corporation, Cambrian BioPharma, and Shin-Etsu Chemical.
Sensei Biotherapeutics operates through Sensei Biotherapeutics, Inc.